# Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

> **NCT02540993** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 5734 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** Finerenone (BAY94-8862)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02540993
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-09-17
- **Primary completion:** 2020-04-14
- **Final completion:** 2020-04-14
- **Target enrollment:** 5734 (ACTUAL)
- **Last updated:** 2023-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02540993

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02540993, "Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02540993. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*